Dosage and usage of talatumumab_ Kanghule

Talatuzumab is an innovative bispecific antibody drug used to treat extensive-stage small cell lung cancer. The drug activates T cells by targeting DLL3 and CD3 to exert anti-tumor effects. It is necessary to pay attention to the dosage adjustment and potential side effects during the medication course. This article will introduce in detail the usage and dosage of talatumumab, key points in the medication course, and possible side effects, to help patients and medical staff better understand and apply this treatment plan.

Talatuzumab dosage and dosage

is designed to maximize efficacy while reducing the risk of adverse reactions, especially cytokine release syndrome (CRS).

Administration and dosage

Talatuzumab is administered by intravenous infusion, with each infusion lasting 1 hour. It is recommended to adopt a stepwise escalation dose regimen: 1 mg is given on the 1st day of cycle 1, increased to 10 mg on the 8th day, and then 10 mg is given every two weeks for maintenance treatment until disease progression or unacceptable toxicity occurs.

Pretreatment and concomitant medication

To reduce the risk of CRS, dexamethasone 8mg (or equivalent dose) needs to be injected intravenously within 1 hour before infusion on days 1 and 8 of cycle 1. Immediately after the infusion, 1 liter of normal saline is infused intravenously for 4-5 hours to promote drug metabolism and excretion.

Monitoring requirements

On days 1 and 8 of Cycle 1, patients must be continuously monitored for 22-24 hours in a medical institution equipped with CRS monitoring and first aid conditions. It is recommended that patients be accompanied by a caregiver for 48 hours after the infusion and remain within a 1-hour drive of a medical facility.

Strictly following these usage and dosage requirements can effectively reduce treatment risks and improve efficacy.

The medication course of talatumumab

The medication regimen of talatumumab needs to be individually adjusted based on patient tolerance and disease progression.

Restart plan after dose delay

If the treatment is delayed for any reason, the restart plan needs to be adjusted according to the delay time and the last dose: if the delay is ≤14 days (1mg dose) or ≤21 days (10mg dose), the original plan can be directly restored; if the delay exceeds the above time, it must be increased from 1mg again.

Dose adjustments during treatment

Assess complete blood count and liver function before each dose. When neutrophils <1.0×10^9/L or platelets <50×10^9/L occur, treatment needs to be suspended and continued after recovery.

Duration of treatment

Talatuzumab treatment needs to be continued until disease progression or unacceptable toxicity occurs.

Side effects of talatumumab

Talatumumab may cause a variety of side effects, which require close monitoring and timely treatment.

Cytokine release syndrome (CRS)

CRS is the most common adverse reaction of talatumumab, manifesting as fever, hypotension, fatigue, etc. Severity is divided into grades 1-4. Grades 1-2 can be treated symptomatically, and grade 3-4 requires suspension or permanent discontinuation of medication and ICU supportive care.

Neurotoxicity

Including immune effector cell-associated neurotoxicity syndrome (ICANS), with symptoms such as confusion and drowsiness. The occurrence of neurological symptoms requires immediate evaluation. In severe cases, treatment may need to be suspended and hormonal therapy used.

Hematological abnormalities

Neutropenia, thrombocytopenia and anemia are common. Routine blood tests need to be monitored regularly, and febrile neutropenia requires immediate treatment.

These side effects should be identified and dealt with in a timely manner during medication, and targeted treatment should be carried out under the guidance of a doctor.